Epirubicin
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Epirubicin: Primary pulmonary lymphoma
One-Sentence Summary
Epirubicin is an anthracycline chemotherapy drug that damages cancer cell DNA by inhibiting topoisomerase II. The TxGNN model predicts it may be useful for primary pulmonary lymphoma, but no clinical trials are registered and no study found tests epirubicin in this disease, so the evidence level is L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Primary pulmonary lymphoma |
| TxGNN Prediction Score | 0.9971 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Epirubicin belongs to the anthracycline class (a topoisomerase II inhibitor and DNA intercalator), and drugs of this class are used in some lymphoma regimens, such as CEOP and VEBEP. This gives a plausible biological link to lymphoid malignancies, including primary pulmonary lymphoma.
The link is indirect, however. The modern standard for diffuse large B-cell lymphoma is built on doxorubicin (R-CHOP, Pola-R-CHP), not epirubicin, and epirubicin has not been specifically evaluated in primary pulmonary lymphoma. The high model score should therefore be treated as a hypothesis, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the retrieved publications tests epirubicin in primary pulmonary lymphoma. The most relevant items are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7686469 | 1993 | Review | Drugs | General review of epirubicin pharmacology and use in cancer chemotherapy; not specific to lung lymphoma |
| 39192408 | 2024 | Cohort | Zhongguo Shi Yan Xue Ye Xue Za Zhi | Retrospective single-centre analysis of primary extranodal DLBCL in the rituximab era |
| 40728626 | 2025 | Cohort | Annals of Hematology | Pola-R-CHP (doxorubicin-based) in first-line DLBCL, 117 patients retrospectively |
| 10526668 | 1999 | Cohort | The Cancer Journal from Scientific American | VEBEP plus involved-field radiotherapy in advanced Hodgkin’s disease |
| 1866500 | 1991 | Case report | Revista de Investigacion Clinica | Case of primary non-Hodgkin’s lymphoma of the lung |
| 36237246 | 2022 | Case report | Translational Cancer Research | Pleural MALT lymphoma, misdiagnosis case report and review |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02324091 | EPIRUBICIN FOR INJECTION | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (anthracycline) |
| Myelosuppression Risk | High (myelosuppression is a recognised dose-limiting effect of anthracyclines) |
| Emetogenicity Classification | Moderate |
| Monitoring Items | CBC with differential, liver and renal function, cardiac function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction database. Major-level interactions in the listed results include cimetidine and dolasetron. Many others are moderate, for example acarbose, famotidine, pioglitazone, loperamide, bupropion, clarithromycin, levofloxacin and naltrexone.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a high model score alone (evidence level L5). No trial is registered and no study directly tests epirubicin in primary pulmonary lymphoma. Doxorubicin-based regimens remain the standard for related lymphomas.
To proceed, the following is needed:
- Disease-specific clinical or preclinical data on epirubicin in primary pulmonary lymphoma
- Mechanism-of-action data and package insert warnings and contraindications
- A comparison with current standard lymphoma regimens, including cardiotoxicity and secondary leukaemia risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.